916891-97-9

Basic information

• Product Name: tert-Butyl imidazolidine-1-carboxylate
• Synonyms: tert-Butyl imidazolidine-1-carboxylate
• CAS NO: 916891-97-9
• Molecular Formula: C₈H₁₆N₂O₂
• Molecular Weight: 172.22484
• Mol File: 916891-97-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: tert-Butyl imidazolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl imidazolidine-1-carboxylate(916891-97-9)
• EPA Substance Registry System: tert-Butyl imidazolidine-1-carboxylate(916891-97-9)

Safety Data

• Hazardous Substances Data: 916891-97-9(Hazardous Substances Data)

Usage

Uses

Used in Personal Care Products:
Tert-Butyl imidazolidine-1-carboxylate is used as a stabilizer in personal care products to protect against the effects of oxidation and degradation in formulations. Its skin-conditioning properties make it a common ingredient in skincare and hair care products.
Used in Pharmaceuticals:
In the pharmaceutical industry, tert-Butyl imidazolidine-1-carboxylate is used as a stabilizer to prevent oxidation and degradation in formulations, ensuring the stability and efficacy of the products.
Used in Agriculture:
Tert-Butyl imidazolidine-1-carboxylate is used in agriculture as a stabilizer to protect formulations from oxidation and degradation, ensuring the effectiveness of the products.
Used as Antimicrobial and Antifungal Agent:
Tert-Butyl imidazolidine-1-carboxylate has been studied for its potential antimicrobial and antifungal activities, making it a versatile and multifunctional ingredient in various applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT

Compounds that function as kinase inhibitors are provided. The kinase inhibitors can have any structure of the formulae provided herein, such as shown for Compounds 1-4. A pharmaceutical composition can include: the compound of one of the embodiments; and

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.